z-logo
Premium
High doses of recombinant α‐interferon or γ‐interferon for chronic hepatitis C: A randomized, controlled trial
Author(s) -
Sáezroyuela Federico,
Porres Juan Carlos,
Moreno Alberto,
Castillo Inmaculada,
Martinez Gracia,
Galiana Fernando,
Carreño Vicente
Publication year - 1991
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840130220
Subject(s) - interferon , medicine , hepatology , gastroenterology , interferon alfa , alpha interferon , hepatitis c , chronic hepatitis , immunology , virus
Chronic hepatitis C is often a progressive liver disease for which there is no satisfactory treatment. We studied the efficacy of recombinant α‐interferon or γ‐interferon in the treatment of this disease in comparison with a control group. Thirty patients were randomly assigned to three groups. Ten patients received 7.5 MU α‐interferon/m 2 body surface three times weekly for 3 mo, then 5 MU/m 2 for 3 mo and 2.5 MU/m 2 for 6 mo. Ten patients were treated with γ‐interferon at a dose of 2 MU/m 2 for 6 mo and the other 10 served as controls without treatment. The mean serum ALT levels and liver histological findings improved significantly only in the patients treated with α‐interferon. No changes were observed in patients treated with γ‐interferon or in controls. Five of 10 patients treated with α‐interferon had complete responses (mean ALT normal during therapy). After treatment ALT returned to pretreatment levels in two of 5 patients. The long‐term response rate after α‐interferon therapy was 30% at 18 mo. We conclude that α‐interferon is effective in controlling disease activity in a portion of patients with chronic hepatitis C. High doses of α‐interferon do not appear to add further benefit in the response rate or relapse rate. γ‐Interferon therapy is ineffective. (H EPATOLOGY 1991;13:327–331).

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here